Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Johnson & Johnson (NY:JNJ)

242.49 -4.42 (-1.79%)

Official Closing Price Updated: 7:00 PM EST, Feb 20, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	13,565,816
Open	246.47
Bid (Size)	242.50 (200)
Ask (Size)	242.87 (200)
Prev. Close	246.91
Today's Range	240.28 - 246.88
52wk Range	141.50 - 246.96
Shares Outstanding	2,628,679,824
Dividend Yield	2.14%

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Economic Stagnation: Q4 2025 GDP Misses Mark as Government Shutdown Hangs Heavy Over 2026 Outlook

February 20, 2026

The U.S. economy faced a sobering reality check on Friday as the Bureau of Economic Analysis (BEA) released its preliminary reading for the fourth quarter of 2025. Gross Domestic Product (GDP) grew at...

Via MarketMinute

Friday's session: gap up and gap down stock in the S&P500 index ↗

February 20, 2026

Via Chartmill

Performance

YTD	+16.9%	+16.9%
1 Month	+11.2%	+11.2%
3 Month	+18.9%	+18.9%
6 Month	+35.3%	+35.3%
1 Year	+51.9%	+51.9%

More News

JNJ Stock Rises As Drugmaker Reportedly Eyes Orthopedics Segment Sale For Up To $20B ↗

February 19, 2026

Via Stocktwits

Johnson & Johnson (NYSE:JNJ) Stands Out as a High-Quality Dividend Aristocrat for Income Investors ↗

February 07, 2026

Via Chartmill

Health Care Sector (XLV) Shows Resilience Amid Tech Volatility and Strong Jobs Data

February 18, 2026

Via MarketMinute

Johnson & Johnson Expands U.S. Footprint with more than $1 Billion Investment in Next Generation Cell Therapy Manufacturing Facility in Pennsylvania

February 18, 2026

From Johnson & Johnson

Via Business Wire

FDA Grants Breakthrough Status To Johnson & Johnson's Cancer Drug For Advanced Head and Neck Cancer ↗

February 18, 2026

Via Benzinga

Behind the Scenes of Johnson & Johnson's Latest Options Trends ↗

February 17, 2026

Via Benzinga

Johnson & Johnson's New FDA Approval Lets Lung Cancer Patients Switch To Monthly Dosing Sooner ↗

February 17, 2026

Via Benzinga

Why Late-Stage CNS, Oncology Assets Are Becoming the Hottest Targets in Biotech M&A

February 17, 2026

From BioMedWire

Via GlobeNewswire

The Seven-Thousand Siege: S&P 500’s Historic Breach and the Great Tech Pivot of 2026

February 16, 2026

Via MarketMinute

ASCO GU 2026: Merck and Protara Poised to Disrupt Bladder and Kidney Cancer Standards

February 16, 2026

Via MarketMinute

Jury: Johnson & Johnson Liabile in Case Linking Baby Powder to Cancer ↗

February 14, 2026

Via Benzinga

Philadelphia Jury Returns $250,000 Verdict Against J&J in Latest Baby Powder-Ovarian Cancer Trial

February 13, 2026

From Beasley Allen Law Firm

Via Business Wire

Volatility Returns to Wall Street: VIX Surges 18% as AI Fatigue Triggers Massive Three-Day Sector Rotation

February 13, 2026

Via MarketMinute

"Blowout" Jobs Report Ignites 2026 Growth Hopes as Unemployment Hits 4.3% Floor

February 13, 2026

Via MarketMinute

The Great Rebound: US M&A Market Ignites as Megadeals Surge 111% in AI-Driven Supercycle

February 12, 2026

Via MarketMinute

Is Johnson & Johnson a Buy, Sell, or Hold in 2026? ↗

February 10, 2026

Via The Motley Fool

Novel Serotonergic Agonists Positioned to Capture Share of $150B+ Neuropsychiatric Market

February 10, 2026

Via FinancialNewsMedia

Johnson & Johnson to Participate in the Barclays 28th Annual Global Healthcare Conference

February 09, 2026

From Johnson & Johnson

Via Business Wire

5 Stocks and ETFs to Help Shield Your Portfolio During Volatility ↗

February 09, 2026

Via MarketBeat

Johnson & Johnson Reports 90% AFib Freedom In Early Heart Device Study ↗

February 09, 2026

Via Benzinga

What is Considered a Good Stock Dividend? 2 Healthcare Stocks That Fit the Bill. ↗

February 08, 2026

Via The Motley Fool

Johnson & Johnson Presents Early Outcomes from the OMNY-AF Pilot Study at 2026 AF Symposium

February 06, 2026

From Johnson & Johnson

Via Business Wire

Eli Lilly Booms, Then Busts: Stellar Guidance vs Hims Undercut ↗

February 06, 2026

Via MarketBeat

Frequently Asked Questions

Is Johnson & Johnson publicly traded?

Yes, Johnson & Johnson is publicly traded.

What exchange does Johnson & Johnson trade on?

Johnson & Johnson trades on the New York Stock Exchange

What is the ticker symbol for Johnson & Johnson?

The ticker symbol for Johnson & Johnson is JNJ on the New York Stock Exchange

What is the current price of Johnson & Johnson?

The current price of Johnson & Johnson is 242.49

When was Johnson & Johnson last traded?

The last trade of Johnson & Johnson was at 02/20/26 07:00 PM ET

What is the market capitalization of Johnson & Johnson?

The market capitalization of Johnson & Johnson is 637.43B

How many shares of Johnson & Johnson are outstanding?

Johnson & Johnson has 637B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.